Compare GSK plc (GSK) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs VNET Group Inc — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while VNET Group Inc trades at $5.48 (market cap $1.47B). The key difference: GSK plc is far larger — about 62.5× VNET Group Inc's market cap, and GSK plc pays a 3.9% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and VNET Group Inc for 16 Days on average.
| GSK | VNET | |
|---|---|---|
Market Cap | $91.88B | $1.47B |
Volume | 7,730,529 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $61.18 | $14.03 |
52-Week Low | $43.24 | $5.13 |
Typical Hold Time | 93 Days | 16 Days |
Enterprise Value | $111.88B | $5.04B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
VNET trades at $5.42, up 0.56% today but near a 52-week low. Technicals are bearish with moving averages signaling sell, while fundamentals show revenue growth to $9.95B in 2025 but net losses of $256.77M. Recent news includes a strategic investment closing and a new low, reflecting mixed sentiment amid high institutional interest and negative cash flow trends.
Outlook: Strategic partnerships and AI demand offer growth, but high debt, negative margins, and bearish technicals pose significant risks. Analyst consensus is moderately bullish (62.5% buy), yet profitability challenges and leverage require caution for investors seeking turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
